ReviewCurrent diabetes reports2015
The evolving understanding of the contribution of lipid metabolism to diabetic kidney disease.
Review in Current diabetes reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 2 syntheses or guidelines pooled it, 173 citations in OpenAlex.
- Association between remnant cholesterol and chronic kidney disease: Systematic review and meta-analysis.Diabetes, obesity & metabolism · 2025Pooled it
- Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease.Frontiers in immunology · 2023Pooled it
- Serum metabolic profiling analysis of Gitelman syndrome using untargeted metabolomics.Renal failure · 2026Article
- Relationship between remnant cholesterol and acute kidney injury in ICU patients: insights derived from MIMIC IV.International urology and nephrology · 2026Article
- Isoquercitrin Improves Renal Tubular Epithelial Cell Mitochondrial Dysfunction by Regulating Extracellular Signal-Regulated Kinase/Reactive Oxygen Species Signaling and Connexin 43 Expression in Diabetic Kidney Disease.Phytotherapy research : PTR · 2026Article
- Renal function-improving action of Pentadecyl®, a multifunctional triglyceride fromExperimental and therapeutic medicine · 2026Article
- Abnormal lipid metabolism in senescent renal tubular cells in diabetic nephropathy.Cellular and molecular life sciences : CMLS · 2026Review
- Canagliflozin Promotes Structural and Functional Changes in Proximal Tubular Cell Mitochondria of Hypertensive-Diabetic Mice.International journal of molecular sciences · 2025Article
- Article
- The role of redox signaling in mitochondria and endoplasmic reticulum regulation in kidney diseases.Archives of toxicology · 2025Review
- Article
- Longitudinal non-targeted metabolomic profiling of urine samples for monitoring of kidney transplantation patients.Renal failure · 2024Article
- Elevated ALOX12 in renal tissue predicts progression in diabetic kidney disease.Renal failure · 2024Article
- Simvastatin reduces chronic kidney disease and renal failure risk in type 2 diabetes patients: post hoc ACCORD trial analysis.Diabetology & metabolic syndrome · 2024Article
- Aldehyde dehydrogenase 2 preserves kidney function by countering acrolein-induced metabolic and mitochondrial dysfunction.JCI insight · 2024Article
- A pilot study on the differential urine proteomic profile of subjects with community-acquired acute kidney injury who recover versus those who do not recover completely at 4 months after hospital discharge.Frontiers in medicine · 2024Article
- Article
- Modulating effects of crocin on lipids and lipoproteins: Mechanisms and potential benefits.Heliyon · 2024Review
- High-Dose Fenofibrate Stimulates Multiple Cellular Stress Pathways in the Kidney of Old Rats.International journal of molecular sciences · 2024Article
- Targeting de novo lipogenesis to mitigate kidney disease.The Journal of clinical investigation · 2024Article
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Although diabetes is mainly diagnosed based on elevated glucose levels, dyslipidemia is also observed in these patients. Chronic kidney disease (CKD), a frequent occurrence in patients with diabetes, is associated with major abnormalities in circulating lipoproteins and renal lipid metabolism. At baseline, most renal epithelial cells rely on fatty acids as their energy source. CKD, including that which occurs in diabetes, is characterized by tubule epithelial lipid accumulation. Whether this is due to increased uptake or greater local fatty acid synthesis is unknown. We have recently shown that CKD also leads to decreased fatty acid oxidation, which might be an additional mechanism leading to lipid accumulation. Defective fatty acid utilization causes energy depletion resulting in increased apoptosis and dedifferentiation, which in turn contributes to fibrosis and CKD progression. Enhanced fatty acid oxidation in the kidney induced by fenofibrate, a peroxisomal proliferator-activated receptor (PPAR)-α agonist, showed benefit in mouse models of CKD. Fenofibrate treatment also reduced albuminuria in patients with diabetes in multiple clinical trials. Taken together, these findings suggest that further understanding of lipid metabolism in diabetic kidney disease may lead to novel therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.